INTRODUCTION AND OBJECTIVES: Long non-coding RNAs (lncRNAs) are important regulators in pathological processes, yet their potential roles in the progression of bladder cancer (BCa) are poorly understood. Understanding the molecule mechanisms is critical to effective treatment of BCa.
METHODS: In this study, we identified lncRNA-BNCA by Microarray results and evaluated the level of lncRNA-BNCA in BCa tissues and cell lines by ISH and qPCR. Both in vitro and in vivo models were used to demonstrate the role of lncRNA-BNCA on the progression of BCa. Moreover, the potential mechanism evaluated levels of of lncRNA-BNCA was explored by RNA pull down and RIP experiments.
RESULTS: Here, we found that a novel lncRNA, lncRNA-BNCA, was upregulated in BCa and cell lines. Knockdown of lncRNA-BNCA impaired cell proliferation and invasion and induced cell apoptosis in vitro, whereas overexpression of lncRNA-BNCA had the opposite effect. Consistently, the growth and invasion effect of lncRNA-BNCA was also demonstrated in vivo. We further demonstrate a distinct mode of lncRNA-mediated gene regulation, wherein lncRNA-BNCA binds to the heterogeneous nuclear ribonucleoprotein (hnRNP) Q protein to restrain p53 protein induction via translation initiation regulation. These effects of lncRNA-BNCA were shown to be clinically relevant, as lncRNA-BNCA was found to be significantly correlated with malignant progression and poor survival.
CONCLUSIONS: Hence, lncRNA-BNCA provides an epigenetic mechanism that restrain the translation efficiency of p53 and may represent a new therapeutic target and prognostic marker. were determined both in vitro and in vivo. Besides, bioinformatic databases including Starbase and CircInteractome were used to investigate the regulating relationship between circ-ITCH and miR-17 in bladder cancer cells. Western blotting was performed to detect the expression of p21 as a target of miR-17. Finally, the mechanism of competing endogenous RNA (ceRNA) between circ-ITCH and miR-17 was determined using bioinformatic analysis and luciferase assays. RESULTS: Circ-ITCH was significantly down-regulated in bladder cancer tissues and cell lines. Overexpression of circ-ITCH exerted tumor-suppressive effects by inhibiting cell proliferation, migration and invasion in vitro and tumor growth in vivo. Furthermore, an inverse relationship between circ-ITCH and miR-17 was found. Circ-ITCH could partly abolish the effect that miR-17 targets p21 and lowers its expression consequently.
CONCLUSIONS: circ-ITCH is down-regulated significantly in bladder cancer, and the newly identified circ-ITCH/miR-17/p21 axis could be a potential biomarkers or therapeutic targets for bladder cancer patients.
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MP48-16 TARGETING ERBB2 MUTATIONS IN UROTHELIAL CARCINOMA
INTRODUCTION AND OBJECTIVES: ERBB2 encodes Human Epidermal growth factor Receptor 2 (HER2), a member of the EGFR family of receptor tyrosine kinases that signal through the pro-oncogenic MAP-and PI3K-kinase pathways. ERBB2 is altered by amplification and/or overexpression in various cancers, including urothelial carcinoma (UC). These alterations could confer sensitivity to ERBB2 kinase inhibitors in selected patients with UC.
METHODS: Patients diagnosed with UC were enrolled onto an institutional review board approved prospective sequencing protocol. Tumor and matched germline DNA were analyzed using the MSK-IMPACT assay that detects alterations in 410 oncogenes and tumor suppressor genes, including ERBB2.
